Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAFFR CART for Relapsed/Refractory Neuromyelitis Optica Spectrum Disorder
NCT06561009Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Dec 2026
- Primary completion
- Oct 2027
- Modality
- CAR-T Cells
01
Overview
A Phase 2 trial of Anti-BAFFR CART in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Tianjin Medical University General Hospital. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
Anti-BAFFR CART
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT06561009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561009.